A Smart + Strong Site
Subscribe to:
E-newsletters
POZ magazine
JOIN AIDSMEDS YouTube

Back to home » Treatment News » Top Stories

Most Popular Stories
An Almost Normal Life Expectancy for People With HIV?
Undetectable Viral Load Essentially Eliminates Transmission Risk in Straight Couples
A 15-Year Jump in Life Expectancy for People With HIV
Misleading News Reports Suggest HIV Cure Is Near
New HIV Drug Class Shows Promise
Gene Therapy Shows Promise in Controlling HIV
Potential Microbicide Tricks HIV Into Sudden Death
What's That Mean?
(just double-click it!)

If you don't understand one of the words in this article, just double-click it. A window will open with a definition from mondofacto's On-line Medical Dictionary. If the double-click feature doesn't work in your browser, you can enter the word below:

Most Popular Lessons
Aging & HIV
The HIV Life Cycle
Shingles
Herpes Simplex Virus
Syphilis & Neurosyphilis
Treatments for Opportunistic Infections (OIs)
What is AIDS & HIV?
More News

Have medical or treatment news about HIV? Send press releases, news tips and other announcements to news@aidsmeds.com.

Click here for more news


emailprint

August 27, 2012

'Quad' Stribild Combo Tablet Approved by FDA

by Tim Horn

Stribild, the once-daily four-in-one fixed-dose combination (FDC) tablet formerly known as the “Quad,” has been approved for people living with HIV initiating antiretroviral (ARV) therapy for the first time, according to announcements by Gilead Sciences and the U.S. Food and Drug Administration released on Monday, August 27.

The tablet contains two new antiretrovirals—the integrase inhibitor elvitegravir and the novel pharmacokinetics enhancer cobicistat (needed to boost blood levels of elvitegravir)—as well as the nucleotide/nucleoside analog pair Truvada (tenofovir and emtrictabine).

The approval of Stribild is supported by 48-week data from two Phase III clinical trials (Studies 102 and 103) in which the single-tablet regimen was found comparable to Atripla and Norvir (ritonavir)-boosted Reyataz plus Truvada.

Like labels of many other ARVs, Stribild’s package insert carries a Boxed Warning alerting people living with HIV and their health care providers that the drug can cause a build up of lactic acid in the blood and severe liver problems, both of which can be fatal. The Boxed Warning also states that Stribild is not approved to treat chronic hepatitis B virus infection.

Common side effects observed in clinical trials include nausea and diarrhea. Serious side effects include new or worsening kidney problems, decreased bone mineral density, fat redistribution and changes in the immune system (immune reconstitution syndrome). 

Stribild’s label gives advice to health care providers on how to monitor patients for kidney or bone side effects.

Stribild's per-patient annual wholesale acquisition cost (WAC) is $28,500, according to a Gilead spokesperson. The per-patient WAC for Atripla (efavirenz plus tenofovir and emtricitabine), Gilead’s current leading once-daily FDC tablet, is $21,000.

A patient assistance program—Gilead’s U.S. Advancing Access initiative—will provide assistance to people living with HIV who do not have insurance or who need financial assistance to pay for their ARVs, including Stribild.   Patients may contact Advancing Access at 1-800-226-2056 between 9:00 AM and 8:00 PM (Eastern Time) to see if they are eligible for the program.

For people living with HIV who have private insurance, Gilead’s co-pay program provides assistance with out-of-pocket expenses for Gilead’s HIV medications, including Stribild, starting at the first dollar.  Additionally, Gilead is working closely with the ADAP Crisis Task Force, as the company has done for each of its other HIV medications, to provide discounts to state AIDS Drug Assistance Programs (ADAPs) that will help ensure access to Stribild for people living with HIV who receive medications through these programs.

Applications for marketing approval of Stribild are pending in Australia, Canada and the European Union.

In the developing world, Gilead has granted multiple Indian manufacturing partners and the Medicines Patent Pool the right to develop generic versions of Stribild and distribute them to 100 developing countries.  These agreements include a complete technology transfer of the manufacturing process for the single tablet regimen.

Search: quad, stribild, elvitegravir, cobicistat, tenofovir, emtricitabine, truvada, atripla, fda, approved


Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The AIDSmeds team reviews all comments before they are posted. Please do not include ":" "@" "<" ">" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Show comments (5 total)


[Go to top]

Quick Links
AIDSmeds en Español
About HIV and AIDS
Lab Tests
Clinical Trials
HIV Meds
Starting Treatment
Switching Treatment
Drug Resistance
Side Effects
Disclosure
Lipodystrophy
Hepatitis & HIV
Women & Children
Fact Sheets
Treatment News
Community Forums
Blogs
Conference Coverage
Health Services Directory
POZ Magazine


    acousticmat
    Tucson
    Arizona


    Poz_Qt
    Columbus
    Ohio


    Deelight4u
    BROOKLYN
    New York

This could be you!
Click here to join POZ Personals!
Conference Coverage

21st Conference on Retroviruses and Opportunistic Infections
(CROI 2014)
Boston, MA
March 3 - 7, 2014


7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention
(IAS 2013)
Kuala Lumpur, Malaysia
June 30 - July 3, 2013


20th Conference on Retroviruses and Opportunistic Infections
(CROI 2013)
Atlanta, GA
March 3 - 7, 2013


more conference coverage

[ about AIDSmeds | AIDSmeds advisory board | our staff | advertising policy | advertise/contact us]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.